APRIL 05, 2016
TORONTO, ONTARIO — (Marketwired) — 04/05/16 — Supreme Pharmaceuticals Inc. (the “Company” or “Supreme”) (CSE:SL) (OTC PINK:SPRWF) is pleased to announce it has established a strategic alliance (the “Strategic Alliance”) with top international cannabis seed developer Dinafem Seeds (“Dinafem”) based in San Sebastian, Spain. Since 2002, Dinafem has been a global leader in the innovation and standardization of cannabis genetics including pioneering many feminized and auto-flowering varieties.
Dinafem has won numerous awards at cannabis competitions including: Treating Yourself, ( Canada); the Highlife Cup ( Holland); and Spannabis ( Spain). Dinafem has also made considerable strides in the development of CBD rich cannabis varieties, offering THC:CBD ratios of 1:1, 1:2 and 1:3 as well as low THC high CBD varieties. As a result of the Strategic Alliance, Supreme will benefit from Dinafem’s decades of research, development and product expertise.
“We are excited Supreme will be utilizing our genetics in their hybrid greenhouse,” stated Mr. Gorospe, CEO of Dinafem. “Supreme’s commitment to producing high quality, sun grown cannabis is aligned with our own commitment to producing the best genetics. Dinafem is focused on market leading innovation in cannabis genetics, striving to maximize the potential of each variety. With each innovation we create seeds optimized for output, potency and consumer appeal. Supreme understands the importance of starting from seed and the value of future genetic stock. We look forward to working with Supreme to introduce our genetics to the Canadian market.”
Pursuant to the Strategic Alliance, Dinafem will supply Supreme’s wholly owned subsidiary AMMCan, with high quality cannabis seeds to be utilized in Supreme’s 7 acre (342,000 sq. ft.) facility in Kincardine, Ontario. Dinafem will also supply Supreme with exclusive ongoing consulting services.
“I have always admired Dinafem as a leader in the international cannabis market,” stated John Fowler, CEO of Supreme. “Dinafem’s commitment to quality and innovation is a perfect match for Supreme. It is critical to start from seed to ensure our plants are ideally suited to our hybrid greenhouse and our business objectives. This creates long-term proprietary value, as genetics selected this year can be produced for decades. Working with Dinafem we ensure we start with the best seeds. In addition, the consulting services will drastically shorten our learning curve. I’m eager to see what Dinafem and Supreme will produce together.”
Dinafem is a Spanish seed bank founded in 2002. Since its origin, Dinafem has worked with global partners to develop an extensive library of sativa, indica, hybrid and CBD-based genetics and has pioneered the research and development of feminized and auto-flowering cannabis seeds.
Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis through its wholly-owned subsidiary AMMCan. AMMCan is a federally licensed producer of medical marijuana pursuant to the MMPR operating a 7 Acre hybrid greenhouse facility. The Hybrid Greenhouse combines the best technology of indoor production with the efficiencies and sustainability of a greenhouse, in a single large-format production footprint. Please visit www.supreme.ca and www.ammcan.com for more information.
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation license, the Company’s ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.
Source: Supreme Pharmaceuticals Inc.